Literature DB >> 23142366

Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice.

Ilse Gantois1, Andreea S Pop, Celine E F de Esch, Ronald A M Buijsen, Tine Pooters, Baltazar Gomez-Mancilla, Fabrizio Gasparini, Ben A Oostra, Rudi D'Hooge, Rob Willemsen.   

Abstract

Fragile X syndrome is caused by lack of FMR1 protein (FMRP) leading to severe symptoms, including intellectual disability, hyperactivity and autistic-like behaviour. FMRP is an RNA binding protein involved in the regulation of translation of specific target mRNAs upon stimulation of metabotropic glutamate receptor 5 (mGluR5) at the synapse. The absence of FMRP leads to enhanced activity of mGluR5 signal transduction pathways. Many conflicting results have been reported regarding social behaviour deficits in Fmr1 knockout mice, and little is known about the involvement of mGluR5 pathways on social behaviour. In this study, a three-chambered task was used to determine sociability and preference for social novelty in Fmr1 knockout mice. Disruption of Fmr1 functioning resulted in enhanced interaction with stranger mouse during sociability while no significant changes were observed during preference for social novelty assay. Chronic administration of a specific mGluR5 antagonist, AFQ056/Mavoglurant, was able to restore sociability behaviour of Fmr1 knockout mice to levels of wild type littermates. These results support the importance of mGluR5 signalling pathways on social interaction behaviour and that AFQ056/Mavoglurant might be useful as potential therapeutic intervention to rescue various behavioural aspects of the fragile X phenotype.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23142366     DOI: 10.1016/j.bbr.2012.10.059

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  35 in total

Review 1.  Moving Toward Integrative, Multidimensional Research in Modern Psychiatry: Lessons Learned From Fragile X Syndrome.

Authors:  Lawrence K Fung; Allan L Reiss
Journal:  Biol Psychiatry       Date:  2015-12-18       Impact factor: 13.382

2.  Detailed In Vitro Pharmacological Characterization of Clinically Tested Negative Allosteric Modulators of the Metabotropic Glutamate Receptor 5.

Authors:  Angela Arsova; Thor C Møller; Line Vedel; Jakob Lerche Hansen; Simon R Foster; Karen J Gregory; Hans Bräuner-Osborne
Journal:  Mol Pharmacol       Date:  2020-05-01       Impact factor: 4.436

Review 3.  Developing Medications Targeting Glutamatergic Dysfunction in Autism: Progress to Date.

Authors:  Lawrence K Fung; Antonio Y Hardan
Journal:  CNS Drugs       Date:  2015-06       Impact factor: 5.749

4.  Longitudinal identification of clinically distinct neurophenotypes in young children with fragile X syndrome.

Authors:  Jennifer L Bruno; David Romano; Paul Mazaika; Amy A Lightbody; Heather Cody Hazlett; Joseph Piven; Allan L Reiss
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-18       Impact factor: 11.205

Review 5.  Translational Mouse Models of Autism: Advancing Toward Pharmacological Therapeutics.

Authors:  Tatiana M Kazdoba; Prescott T Leach; Mu Yang; Jill L Silverman; Marjorie Solomon; Jacqueline N Crawley
Journal:  Curr Top Behav Neurosci       Date:  2016

6.  The utility of rodent models of autism spectrum disorders.

Authors:  Maria T Lázaro; Peyman Golshani
Journal:  Curr Opin Neurol       Date:  2015-04       Impact factor: 5.710

Review 7.  Genetic Approaches to Understanding Psychiatric Disease.

Authors:  Jacob J Michaelson
Journal:  Neurotherapeutics       Date:  2017-07       Impact factor: 7.620

Review 8.  Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome.

Authors:  Elizabeth M Berry-Kravis; Lothar Lindemann; Aia E Jønch; George Apostol; Mark F Bear; Randall L Carpenter; Jacqueline N Crawley; Aurore Curie; Vincent Des Portes; Farah Hossain; Fabrizio Gasparini; Baltazar Gomez-Mancilla; David Hessl; Eva Loth; Sebastian H Scharf; Paul P Wang; Florian Von Raison; Randi Hagerman; Will Spooren; Sébastien Jacquemont
Journal:  Nat Rev Drug Discov       Date:  2017-12-08       Impact factor: 84.694

9.  Social Communication is an Emerging Target for Pharmacotherapy in Autism Spectrum Disorder - A Review of the Literature on Potential Agents.

Authors:  Danielle A Baribeau; Evdokia Anagnostou
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2014-02

Review 10.  From FMRP function to potential therapies for fragile X syndrome.

Authors:  Ferzin Sethna; Changjong Moon; Hongbing Wang
Journal:  Neurochem Res       Date:  2013-12-18       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.